334 related articles for article (PubMed ID: 25236375)
1. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.
Hamnvik OP; Choueiri TK; Turchin A; McKay RR; Goyal L; Davis M; Kaymakcalan MD; Williams JS
Cancer; 2015 Jan; 121(2):311-9. PubMed ID: 25236375
[TBL] [Abstract][Full Text] [Related]
2. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ
J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770
[TBL] [Abstract][Full Text] [Related]
3. Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor-Induced Blood Pressure Rise: A Clinical Cohort Study.
van Dorst DCH; Kabadayi S; Oomen-de Hoop E; Danser AHJ; Mathijssen RHJ; Versmissen J
J Am Heart Assoc; 2023 Jan; 12(1):e028050. PubMed ID: 36583425
[TBL] [Abstract][Full Text] [Related]
4. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
Maitland ML; Kasza KE; Karrison T; Moshier K; Sit L; Black HR; Undevia SD; Stadler WM; Elliott WJ; Ratain MJ
Clin Cancer Res; 2009 Oct; 15(19):6250-7. PubMed ID: 19773379
[TBL] [Abstract][Full Text] [Related]
5. Use of Antihypertensive Drugs in Neoplastic Patients.
Rizzoni D; De Ciuceis C; Porteri E; Agabiti-Rosei C; Agabiti-Rosei E
High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):127-132. PubMed ID: 28361339
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
Sorich MJ; Kichenadasse G; Rowland A; Woodman RJ; Mangoni AA
Int J Cancer; 2016 May; 138(9):2293-9. PubMed ID: 26685869
[TBL] [Abstract][Full Text] [Related]
7. Management of hypertension in angiogenesis inhibitor-treated patients.
Izzedine H; Ederhy S; Goldwasser F; Soria JC; Milano G; Cohen A; Khayat D; Spano JP
Ann Oncol; 2009 May; 20(5):807-15. PubMed ID: 19150949
[TBL] [Abstract][Full Text] [Related]
8. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.
León-Mateos L; Mosquera J; Antón Aparicio L
Redox Biol; 2015 Dec; 6():421-425. PubMed ID: 26386874
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy.
Bilen MA; Durand JB; McQuinn L; Hess KR; Fu S; Falchook GS; Hong DS; Wheler JJ; Said R; Ewer MS; Kurzrock R; Naing A
Invest New Drugs; 2014 Aug; 32(4):717-22. PubMed ID: 24764123
[TBL] [Abstract][Full Text] [Related]
10. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Kim JJ; Vaziri SA; Rini BI; Elson P; Garcia JA; Wirka R; Dreicer R; Ganapathi MK; Ganapathi R
Cancer; 2012 Apr; 118(7):1946-54. PubMed ID: 21882181
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
[TBL] [Abstract][Full Text] [Related]
12. Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors.
Thompson LA; Saseen JJ; O'Bryant CL; Allen RR; Nair KV
J Oncol Pharm Pract; 2015 Aug; 21(4):258-67. PubMed ID: 24727344
[TBL] [Abstract][Full Text] [Related]
13. Uncontrolled Hypertension and Oncology: Clinical Tips.
Kalaitzidis RG; Elisaf MS
Curr Vasc Pharmacol; 2017; 16(1):23-29. PubMed ID: 28413967
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
Kruzliak P; Novák J; Novák M
Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy.
Curwen JO; Musgrove HL; Kendrew J; Richmond GH; Ogilvie DJ; Wedge SR
Clin Cancer Res; 2008 May; 14(10):3124-31. PubMed ID: 18483380
[TBL] [Abstract][Full Text] [Related]
16. Association of Optimal Blood Pressure With Critical Cardiorenal Events and Mortality in High-Risk and Low-Risk Patients Treated With Antihypertension Medications.
Jung HH
JAMA Netw Open; 2019 Aug; 2(8):e199307. PubMed ID: 31441935
[TBL] [Abstract][Full Text] [Related]
17. [Arterial hypertension difficult to control in the elderly patient. The significance of the "white coat effect"].
Amado P; Vasconcelos N; Santos I; Almeida L; Nazaré J; Carmona J
Rev Port Cardiol; 1999 Oct; 18(10):897-906. PubMed ID: 10590654
[TBL] [Abstract][Full Text] [Related]
18. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
Robinson ES; Matulonis UA; Ivy P; Berlin ST; Tyburski K; Penson RT; Humphreys BD
Clin J Am Soc Nephrol; 2010 Mar; 5(3):477-83. PubMed ID: 20056761
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Szmit S; Zaborowska M; Waśko-Grabowska A; Żołnierek J; Nurzyński P; Filipiak KJ; Opolski G; Szczylik C
Kidney Blood Press Res; 2012; 35(6):468-76. PubMed ID: 22688785
[TBL] [Abstract][Full Text] [Related]
20. Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats.
Isobe T; Komatsu R; Honda M; Kuramoto S; Shindoh H; Tabo M
J Toxicol Sci; 2014 Apr; 39(2):237-42. PubMed ID: 24646704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
